Back to results
US 2010/0168382 A1Published application
Neuroplastin derived peptides
OwnerVladimir Berezininventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerVladimir Berezininventor
Estimating the term…
The present invention relates to peptides derived from neuroplastin which are capable of inducing neurite outgrowth by modulating intracellular calcium concentration and activity of intracellular signalling molecules such as Akt, Erk1/2 and CREB through binding and/or modulation of receptor tyrosine kinases including but not limited to Fibroblast Growth Factor receptors (FGFRs). The peptides are derived from neuroplastin or fragments thereof. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein neuroplastin and/or receptor tyrosine kinases, including but not limited to FGFRs, play a prominent role.
A pharmaceutical composition comprising a peptide comprising an amino acid sequence of neuroplastin (SEQ ID NO:1) or a fragment or variant thereof, said peptide being capable of modulating the activity of receptor tyrosine kinases.
The pharmaceutical composition according to any of the preceding claims, wherein said peptide comprises one or more of the following amino acid sequences:
The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of modulating Akt activity.
The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of modulating Erk 1/2 activity.
The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of modulating CREB activation.
The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulating neurite outgrowth.
The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulating cell survival.
The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulating synaptic plasticity.
The pharmaceutical composition according to any of the preceding claims, wherein said peptide is capable of stimulation learning and/or memory.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions wherein modulation of receptor tyrosine kinases is essential.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions wherein modulation of FGFRs is essential.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions of the central or peripheral nervous system.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of a disease or condition wherein stimulation of neural cell differentiation, neural cell survival, neurogenesis, stem cell proliferation, stem cell differentiation, and/or learning and memory is beneficial for recovery from said disease or condition.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of postoperative nerve damage, traumatic nerve damage, impaired myelination of nerve fibers, postischaemic damage, multiinfarct dementia, multiple sclerosis, nerve degeneration associated with diabetes mellitus, neuro-muscular degeneration, schizophrenia, mood disorders, manic depressive disorders, Alzheimer's disease, Parkinson's disease, or Huntington's disease.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of diseases or conditions of the muscles including conditions with impaired function of neuro-muscular connections, or for the treatment of diseases or degenerative conditions of the gonads, pancreas or kidney.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of preventing cell death of heart muscle cells.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of stimulating revascularisation.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of promotion of wound healing.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of inhibiting angiogenesis.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament for treatment of cancer.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of stimulation of the ability to learn and/or of the short and/or long term memory.
The pharmaceutical composition according to any of the preceding claims used for the production of a medicament capable of modulating proliferation and/or differentiation and/or regeneration and/or morphological plasticity of cells.
An antibody capable of binding to an epitope comprising a sequence corresponding to neuroplastin or a fragment thereof or a variant.
An antibody capable of binding to an epitope comprising at least one of the following sequences:
Dependencies are inferred from the claim text.